April 2026
Ayahuasca
What April 2026's 7 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research on ayahuasca published in April 2026 indicates that it shows promise as a rapid-acting intervention for reducing suicidal ideation and depressive symptoms, with consistent evidence from systematic reviews and a large longitudinal study showing improvements in personality, quality of life, and decentering. However, the evidence is limited by small sample sizes, methodological heterogeneity, and a lack of large-scale, rigorous longitudinal studies.
Confidence in the evidence
Low-Moderate- The systematic review (article_id: 28190) included only five studies with methodological heterogeneity, limiting generalizability.
- The large longitudinal study (article_id: 28353) had a substantial sample (n=264) but was observational and lacked a control group.
- The scoping review (article_id: 28223) covered 12 studies but did not provide quantitative synthesis.
- The zebrafish study (article_id: 28220) provides preclinical support but is not directly translatable to humans.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Ayahuasca administration is consistently associated with rapid and significant reductions in suicidal ideation and depressive symptoms in patients with depressive disorders. |
| Symmetrical Global Mental Health (Sym-GMH): Ayahuasca and shipibo traditional medicine for lasting changes in personality and quality of life 2026 | prospective longitudinal study | 264 | Supports | Significant reductions in Neuroticism and Openness, increases in Extraversion, improved quality of life across all domains, and increased decentering capacities with moderate to high effect sizes; 91.7% reported long-term benefits. |
| Single exposure to Ayahuasca reverses chronic stress effects on sociability, anxiety, cortisol, and BDNF in zebrafish 2026 | preclinical animal study | Supports | A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, and reversed changes in cortisol and BDNF levels. | |
| POTENCIAL TERAPÊUTICO DA HOASCA NO TRATAMENTO DA DEPRESSÃO: REVISÃO DE ESCOPO 2026 | scoping review | 12 | Supports | Antidepressant effects of hoasca/ayahuasca are related to DMT and β-carboline interactions, increasing serotonin availability and BDNF production, with rapid and lasting clinical effects. |
| Responsible Ceremonial Medicine: A Review of Current Evidence, Safety Protocols, and Ethical Considerations for Professional Practice 2026 | review | Supports | Reviews clinical evidence for ayahuasca in major depression and treatment-resistant depression, highlighting neuroplasticity mechanisms and safety protocols. |
Ayahuasca administration is consistently associated with rapid and significant reductions in suicidal ideation and depressive symptoms in patients with depressive disorders.
systematic review Sample size: 5
Significant reductions in Neuroticism and Openness, increases in Extraversion, improved quality of life across all domains, and increased decentering capacities with moderate to high effect sizes; 91.7% reported long-term benefits.
prospective longitudinal study Sample size: 264
A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, and reversed changes in cortisol and BDNF levels.
preclinical animal study
Antidepressant effects of hoasca/ayahuasca are related to DMT and β-carboline interactions, increasing serotonin availability and BDNF production, with rapid and lasting clinical effects.
scoping review Sample size: 12
Reviews clinical evidence for ayahuasca in major depression and treatment-resistant depression, highlighting neuroplasticity mechanisms and safety protocols.
review
Points of agreement
- Ayahuasca shows rapid and significant reductions in depressive symptoms and suicidal ideation.
- Therapeutic effects are linked to neuroplasticity, BDNF upregulation, and modulation of brain networks.
- Adverse effects are minimal in controlled settings.
Conflicts
- The systematic review (article_id: 28190) notes methodological heterogeneity among studies, while the scoping review (article_id: 28223) does not address this directly.
- The longitudinal study (article_id: 28353) found a decrease in Openness, which contrasts with some other psychedelic research that often reports increases.
Gaps
- Lack of large-scale, randomized controlled trials with long-term follow-up.
- Durability of effects beyond 12 months is not established.
- Limited data on diverse populations and real-world clinical settings.
- Optimal dosing and treatment protocols are not standardized.